The purpose of the clinical trial is to find out whether RTX-240 is safe, how much RTX-240 needs to be given for it to be effective and how often it should be given to be effective.
Examples of solid tumors include, but are not limited to, breast cancer, kidney cancer, melanoma, non-small cell lung cancer, small cell lung cancer, squamous cell cancer and more.
RTX-240 is given intravenously (IV), which means into a vein by a trained medical professional.
Participants who join the trial will have a doctor’s exam, blood tests and additional lab work before receiving RTX-240.
All necessary travel and lodging costs related to trial participation will be covered by Rubius Therapeutics; the process for patient reimbursement may vary by trial site.
Rubius Therapeutics is committed to the safety of all clinicians and patients participating in the trial. Each trial site has its own procedures to minimize risk of COVID-19 transmission. If you have any questions, please speak directly with your physician.
For more information about the RTX-240 Phase 1/2 clinical trial, please visit clinicaltrials.gov or sign up below to receive more information about the RTX-240 trial.